Skip to main content
Clinical Trials/NCT05745441
NCT05745441
Recruiting
Not Applicable

Dinner Time for Obesity and Prediabetes

Johns Hopkins University3 sites in 1 country32 target enrollmentJuly 5, 2023

Overview

Phase
Not Applicable
Intervention
Late Dinner
Conditions
PreDiabetes
Sponsor
Johns Hopkins University
Enrollment
32
Locations
3
Primary Endpoint
24-hour total fat oxidation
Status
Recruiting
Last Updated
19 days ago

Overview

Brief Summary

Obesity and its metabolic complications are leading causes of global morbidity and mortality. Evidence is mounting that inappropriate timing of food intake contributes to obesity. Specifically, late eating is associated with greater weight gain and metabolic syndrome. However, the mechanism by which late eating harms metabolism is not fully understood but may be related to mis-timing of food intake in relation to the body's endogenous circadian rhythm. Conversely, harmonization of eating timing with endogenous circadian rhythm may optimize metabolic health. In this study the investigators will use gold-standard methods of characterizing circadian rhythm in humans to examine the metabolic impacts food timing relative to endogenous circadian rhythm.

Detailed Description

This is a randomized, cross-over study that examines the metabolic impact of early vs late dinner, as defined by proximity of food intake to an individual's biological night as determined by dim light melatonin onset (DLMO) in normal-weight, healthy adult volunteers and in adults with obesity and prediabetes. Each participant will first undergo circadian phenotyping at the Johns Hopkins Bayview Clinical Research Unit (Baltimore, Maryland), with assessment of DLMO and core body temperature profile, as well as wrist actigraphy. Thereafter, participants will be crossover randomized to (1) a 24-hour metabolic chamber protocol where dinner is eaten 3 hours before DLMO (early dinner), or (2) a 24-hour metabolic chamber protocol where dinner is 1 hour eaten after DLMO (late dinner), both to be performed at the NIH Metabolic Clinical Research Unit (Bethesda, Maryland). The timing and nutritional contents of all meals, as well as sleep timing and duration, will be held constant. Oral \[2H31\] palmitate will be given with each dinner condition to quantify dietary fat oxidation. The 2 dinner conditions will occur in random order, with a 3- to 4-week washout period. The investigators are enrolling both Normal-Weight Healthy (NWH) and Obesity-Prediabetes (OPD) research participants. At this time (5/2023) the investigators are focusing on the NWH group.

Registry
clinicaltrials.gov
Start Date
July 5, 2023
End Date
March 31, 2028
Last Updated
19 days ago
Study Type
Interventional
Study Design
Crossover
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • The investigators are enrolling both Normal-Weight Healthy (NWH) and Obesity-Prediabetes (OPD) research participants.
  • Inclusion Criteria:
  • For the Normal-Weight Healthy (NWH) cohort: Healthy male and female adults, age 18-50, with BMI 18-24.9 kg/m2 inclusively
  • For the Obesity-Prediabetes (OPD) cohort: Male and female adults, age 18-50, with BMI ≥30 kg/m2 and prediabetes
  • All participants must be able to understand study procedures, to comply with the procedures for the entire length of the study and be fully mobile.

Exclusion Criteria

  • Sleep disorder including insomnia, untreated moderate-severe sleep apnea, restless leg syndrome, or narcolepsy
  • Night shift work
  • Extreme delayed sleep phase defined as self-reported routine bedtime later than 1:00 AM or having mid-sleep on free days later than 5:00 AM on the Munich Chronotype Questionnaire (MCTQ) or DLMO later than 24:00
  • Gastroesophageal reflux disease that affects ability to tolerate a dinner close to bedtime
  • Active smoking
  • Current drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements.
  • Diabetes (type 1 or 2) or on any diabetes medications besides metformin
  • Evidence of metabolic or cardiovascular disease, or disease that may influence metabolism (e.g. cancer, thyroid disease)
  • Hemoglobin A1c ≥5.7% for NWH cohort; Hemoglobin A1c ≥6.5% for OPD cohort
  • Hemoglobin \< 10 g/dL

Arms & Interventions

Early Dinner First

Participants will be served dinner and a stable isotope of oral \[2H31\] palmitate to measure fat oxidation, at an early dinner time (before DLMO). This arm will then cross-over to Late Dinner as the second metabolic visit.

Intervention: Late Dinner

Early Dinner First

Participants will be served dinner and a stable isotope of oral \[2H31\] palmitate to measure fat oxidation, at an early dinner time (before DLMO). This arm will then cross-over to Late Dinner as the second metabolic visit.

Intervention: Early Dinner

Early Dinner First

Participants will be served dinner and a stable isotope of oral \[2H31\] palmitate to measure fat oxidation, at an early dinner time (before DLMO). This arm will then cross-over to Late Dinner as the second metabolic visit.

Intervention: Early Dinner tracer

Early Dinner First

Participants will be served dinner and a stable isotope of oral \[2H31\] palmitate to measure fat oxidation, at an early dinner time (before DLMO). This arm will then cross-over to Late Dinner as the second metabolic visit.

Intervention: Late Dinner tracer

Late Dinner First

Participants will be served dinner and a stable isotope of oral \[2H31\] palmitate to measure fat oxidation, at a late dinner time (after DLMO). This arm will then cross-over to Early Dinner as the second metabolic visit.

Intervention: Early Dinner

Late Dinner First

Participants will be served dinner and a stable isotope of oral \[2H31\] palmitate to measure fat oxidation, at a late dinner time (after DLMO). This arm will then cross-over to Early Dinner as the second metabolic visit.

Intervention: Late Dinner

Late Dinner First

Participants will be served dinner and a stable isotope of oral \[2H31\] palmitate to measure fat oxidation, at a late dinner time (after DLMO). This arm will then cross-over to Early Dinner as the second metabolic visit.

Intervention: Early Dinner tracer

Late Dinner First

Participants will be served dinner and a stable isotope of oral \[2H31\] palmitate to measure fat oxidation, at a late dinner time (after DLMO). This arm will then cross-over to Early Dinner as the second metabolic visit.

Intervention: Late Dinner tracer

Outcomes

Primary Outcomes

24-hour total fat oxidation

Time Frame: baseline, 4 weeks

Within-subject difference in total fat oxidation between early dinner and late dinner conditions.

Secondary Outcomes

  • 14-hour post-dinner cumulative dietary fat oxidation(baseline, 4 weeks)
  • 4-hour post-prandial area-under-the-curve insulin levels(baseline, 4 weeks)
  • 4-hour post-prandial area-under-the-curve (AUC) glucose levels(baseline, 4 weeks)

Study Sites (3)

Loading locations...

Similar Trials